Serotonin News and Research

Latest Serotonin News and Research

ADHD genes found - missing DNA segments may suggest future drug targets

Pediatric researchers have identified hundreds of gene variations that occur more frequently in children with attention-deficit hyperactivity disorder (ADHD) than in children without ADHD. Many of those genes were already known to be important for learning, behavior, brain function and neurodevelopment, but had not been previously associated with ADHD.

24 Jun 2009

Major depression, antidepressant medication and the risk of obesity

Cross-sectional studies have reported an association between major depressive episode (MDE) and obesity. The objective of this longitudinal analysis was to determine whether MDE increase the risk of becoming obese over a 10-year period.

23 Jun 2009

Mouse model of Parkinson's reproduces non-motor symptoms

The classic symptoms of Parkinson's disease involve tremor, stiffness and slow movements. Over the last decade, neurologists have been paying greater attention to non-motor symptoms, such as digestive and sleep problems, loss of sense of smell and depression.

23 Jun 2009

Animal model for human gambling

UBC researchers have created the world's first animal laboratory experiment to successfully model human gambling. The advance will help scientists develop and test new treatments for gambling addictions, a devastating condition that affects millions worldwide.

17 Jun 2009

Much touted "depression risk gene" may not add to risk after all

Stressful life events are strongly associated with a person's risk for major depression, but a certain gene variation long thought to increase risk in conjunction with stressful life events actually may have no effect, according to researchers funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health. The study, published in the June 17, 2009, issue of the Journal of the American Medical Association, challenges a widely accepted approach to studying risk factors for depression.

16 Jun 2009

Histamine affects alcohol-related behaviour

The histamine-3 receptor is important in terms of alcohol-related behaviour, and a drug affecting that receptor may have qualities that alter alcohol-related behaviour.

16 Jun 2009

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Eli Lilly and Company has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).

3 Jun 2009

Skin cells provide new knowledge about brain functions

Until now diseases like schizophrenia and bipolar disorder have been difficult to study biologically, since this would entail taking samples from the patient's brain.

3 Jun 2009

FDA antidepressant warnings led to unintended changes in depression diagnosis

Government warnings about suicidality among children taking antidepressants appear to be associated with unintended and persistent changes in the diagnosis and treatment of depression in children and adults, according to a report in the June issue of Archives of General Psychiatry.

1 Jun 2009

Citalopram no more effective than a placebo for children with autism spectrum disorders

Citalopram, a medication commonly prescribed to children with autism spectrum disorders (ASD), was no more effective than a placebo at reducing repetitive behaviors, according to researchers funded by the National Institute of Mental Health (NIMH) and other NIH institutes. The study was published in the June 2009 issue of Archives of General Psychiatry.

1 Jun 2009

oct3 protein key to Parkinson's, drug addiction

Scientists have identified a protein that appears not only to be central to the process that causes Parkinson's disease but could also play a role in muting the high from methamphetamine and other addictive drugs.

4 May 2009

Are we cherry picking participants for studies of antidepressants?

Findings from clinical studies used to gain Food and Drug Administration approval of common antidepressants are not applicable to most patients with depression, according to a report led by the University of Pittsburgh Graduate School of Public Health.

30 Apr 2009

Wrist acupuncture prevents postoperative nausea and vomiting

Up to 80 percent of patients who have surgery complain of nausea and vomiting afterwards, but stimulating an acupoint in their wrists can help reduce these symptoms, finds a new evidence review.

14 Apr 2009

Health problems associated with Chinese slimming capsules

Taking herbal food supplements is certainly not free of risk. Since 2005, the poison emergency centers in the German cities of Freiburg and Gottingen have registered a total of 17 patients with health problems after taking Chinese slimming capsules.

8 Apr 2009

CyDex Pharmaceuticals taste-masking formulation patent and patent application up for sale

IpAuctions, Inc. will auction one pharmaceutical patent and one patent application on behalf of specialty pharmaceutical company CyDex Pharmaceuticals, Inc. of Lenexa, Kansas, USA.

6 Apr 2009

Addressing sleep problems could reduce the risk of suicidal behaviours

In a study presented at the World Psychiatric Association international congress "Treatments in Psychiatry," scientists found that the more types of sleep disturbances people had, the more likely they were to have thoughts of killing themselves, engage in planning a suicidal act or make a suicide attempt.

1 Apr 2009

CSHL neuroscientists propose project to comprehensively map mammalian brain circuits

Thirty-seven scientists from Cold Spring Harbor Laboratory (CSHL) and 20 other major research institutions in the U.S. and Europe have issued a major challenge to the neuroscience community.

1 Apr 2009

p11 protein may lead to faster acting antidepressants

Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

23 Mar 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

Brain protein may be a target for fast-acting antidepressants

It takes weeks or months for the effect of most antidepressants to kick in, time that can feel like an eternity to those who need the drugs the most. But new research suggests that a protein called p11, previously shown to play a role in a person's susceptibility to depression, activates a serotonin receptor in the brain known for producing

25 Feb 2009